S-Nitrosylation of parkin as a novel regulator of p53-mediated neuronal cell death in sporadic Parkinson's disease

Molecular Neurodegeneration

Volumn 8, Issue 1, 2013, Pages

  Sunico, Carmen R ^a   Nakamura, Tomohiro ^a   Rockenstein, Edward ^b   Mante, Michael ^b   Adame, Anthony ^b   Chan, Shing Fai ^a   Newmeyer, Traci Fang ^a   Masliah, Eliezer ^b   Nakanishi, Nobuki ^a   Lipton, Stuart A ^a,b  

^a BURNHAM INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Nitric oxide (NO); Nitrosative stress; p53; Parkin; Parkinson's disease; S nitrosylation

Indexed keywords

NITRIC OXIDE SYNTHASE; PARKIN; PESTICIDE; PROTEIN P53; UBIQUITIN PROTEIN LIGASE E3;

APOPTOSIS; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; GENE MUTATION; HUMAN; MESENCEPHALON; NERVE CELL NECROSIS; NITROSATIVE STRESS; NITROSYLATION; PARKINSON DISEASE; PROTEIN FUNCTION; PROTEIN PROCESSING; REPRESSOR GENE; UBIQUITINATION; UPREGULATION;

MUS;

AGED; AGED, 80 AND OVER; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CHROMATIN IMMUNOPRECIPITATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IN SITU NICK-END LABELING; MALE; MICE; NEURONS; NITRIC OXIDE; PARKINSON DISEASE; PESTICIDES; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 84883072266     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-8-29     Document Type: Article

References (71)

1. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Mayeux R, Marder K, Cote LJ, Denaro J, Hemenegildo N, Mejia H, Tang MX, Lantigua R, Wilder D, Gurland B, et al. Am J Epidemiol 1995 142 820 827 7572958
2. Are ubiquitination pathways central to Parkinson's disease? Giasson BI, Lee VM, Cell 2003 114 1 8 10.1016/S0092-8674(03)00509-9 12859888 (Pubitemid 36859837)
3. Oxidative stress in Parkinson's disease. Jenner P, Ann Neurol 2003 3 53 26 36 discussion S36-28
4. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT, Nat Neurosci 2000 3 1301 1306 10.1038/81834 11100151
5. Parkinson's disease: current and future challenges. Langston JW, Neurotoxicology 2002 23 443 450 10.1016/S0161-813X(02)00098-0 12428715 (Pubitemid 36527664)
6. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N, Nature 1998 392 605 608 10.1038/33416 9560156 (Pubitemid 28207717)
7. Association between early-onset Parkinson's disease and mutations in the parkin gene. Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Denefle P, Wood NW, et al. The New England journal of medicine 2000 342 1560 1567 10.1056/NEJM200005253422103 10824074 (Pubitemid 30340501)
8. Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Oliveira SA, Scott WK, Martin ER, Nance MA, Watts RL, Hubble JP, Koller WC, Pahwa R, Stern MB, Hiner BC, et al. Ann Neurol 2003 53 624 629 10.1002/ana.10524 12730996 (Pubitemid 36529436)
9. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T, Nat Genet 2000 25 302 305 10.1038/77060 10888878 (Pubitemid 30437317)
10. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM, Proc Natl Acad Sci U S A 2000 97 13354 13359 10.1073/pnas.240347797 11078524
11. Impairment of the ubiquitin-proteasome system by protein aggregation. Bence NF, Sampat RM, Kopito RR, Science 2001 292 1552 1555 10.1126/science.292. 5521.1552 11375494 (Pubitemid 32493425)
12. Molecular pathways of neurodegeneration in Parkinson's disease. Dawson TM, Dawson VL, Science 2003 302 819 822 10.1126/science.1087753 14593166 (Pubitemid 37339614)
13. Parkin: a multipurpose neuroprotective agent? Feany MB, Pallanck LJ, Neuron 2003 38 13 16 10.1016/S0896-6273(03)00201-0 12691660 (Pubitemid 36423349)
14. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Jiang H, Ren Y, Zhao J, Feng J, Hum Mol Genet 2004 13 1745 1754 10.1093/hmg/ddh180 15198987 (Pubitemid 39173443)
15. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L, Science 2000 287 1265 1269 10.1126/science.287.5456.1265 10678833 (Pubitemid 30112148)
16. Parkin-associated Parkinson's disease. von Coelln R, Dawson VL, Dawson TM, Cell Tissue Res 2004 318 175 184 10.1007/s00441-004-0924-4 15503153 (Pubitemid 39362637)
17. Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. Henn IH, Bouman L, Schlehe JS, Schlierf A, Schramm JE, Wegener E, Nakaso K, Culmsee C, Berninger B, Krappmann D, et al. The Journal of neuroscience: the official journal of the Society for Neuroscience 2007 27 1868 1878 10.1523/JNEUROSCI.5537-06.2007
18. The ubiquitin E3 ligase parkin regulates the proapoptotic function of Bax. Johnson BN, Berger AK, Cortese GP, Lavoie MJ, Proc Natl Acad Sci U S A 2012 109 6283 6288 10.1073/pnas.1113248109 22460798
19. Apoptosis in Parkinson's disease: is p53 the missing link between genetic and sporadic Parkinsonism? Alves Da Costa C, Checler F, Cell Signal 2011 23 963 968 10.1016/j.cellsig.2010.10.020 20969953
20. Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. da Costa CA, Sunyach C, Giaime E, West A, Corti O, Brice A, Safe S, Abou-Sleiman PM, Wood NW, Takahashi H, et al. Nat Cell Biol 2009 11 1370 1375 10.1038/ncb1981 19801972
21. Nitrosative and oxidative stress links dysfunctional ubiquitination to Parkinson's disease. Gu Z, Nakamura T, Yao D, Shi ZQ, Lipton SA, Cell Death Differ 2005 12 1202 1204 10.1038/sj.cdd.4401705 16094397 (Pubitemid 41195105)
22. Gene-environment interactions in Parkinson's disease and other forms of parkinsonism. Vance JM, Ali S, Bradley WG, Singer C, Di Monte DA, Neurotoxicology 2010 31 598 602 10.1016/j.neuro.2010.04.007 20430055
23. Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Wang C, Ko HS, Thomas B, Tsang F, Chew KC, Tay SP, Ho MW, Lim TM, Soong TW, Pletnikova O, et al. Hum Mol Genet 2005 14 3885 3897 10.1093/hmg/ddi413 16278233 (Pubitemid 43020090)
24. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Chung KK, Thomas B, Li X, Pletnikova O, Troncoso JC, Marsh L, Dawson VL, Dawson TM, Science 2004 304 1328 1331 10.1126/science.1093891 15105460 (Pubitemid 38697430)
25. Oxidation of the cysteine-rich regions of parkin perturbs its E3 ligase activity and contributes to protein aggregation. Meng F, Yao D, Shi Y, Kabakoff J, Wu W, Reicher J, Ma Y, Moosmann B, Masliah E, Lipton SA, Gu Z, Mol Neurodegener 2011 6 34 10.1186/1750-1326-6-34 21595948
26. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Yao D, Gu Z, Nakamura T, Shi ZQ, Ma Y, Gaston B, Palmer LA, Rockenstein EM, Zhang Z, Masliah E, et al. Proc Natl Acad Sci U S A 2004 101 10810 10814 10.1073/pnas.0404161101 15252205 (Pubitemid 38955824)
27. Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Costello S, Cockburn M, Bronstein J, Zhang X, Ritz B, Am J Epidemiol 2009 169 919 926 10.1093/aje/kwp006 19270050
28. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, Chen RC, Neurology 1997 48 1583 1588 10.1212/WNL.48.6.1583 9191770
29. Parkinsonism after chronic exposure to the fungicide maneb (manganese ethylene-bis-dithiocarbamate). Meco G, Bonifati V, Vanacore N, Fabrizio E, Scandinavian journal of work, environment & health 1994 20 301 305 10.5271/sjweh.1394 23619798 (Pubitemid 24291313)
30. Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats. Cicchetti F, Lapointe N, Roberge-Tremblay A, Saint-Pierre M, Jimenez L, Ficke BW, Gross RE, Neurobiol Dis 2005 20 360 371 10.1016/j.nbd.2005.03.018 16242641 (Pubitemid 41476262)
31. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease? Thiruchelvam M, Brockel BJ, Richfield EK, Baggs RB, Cory-Slechta DA, Brain research 2000 873 225 234 10.1016/S0006-8993(00)02496-3 10930548 (Pubitemid 30619046)
32. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. Thiruchelvam M, Richfield EK, Baggs RB, Tank AW, Cory-Slechta DA, The Journal of neuroscience: the official journal of the Society for Neuroscience 2000 20 9207 9214 (Pubitemid 32042923)
33. Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype. Thiruchelvam M, Richfield EK, Goodman BM, Baggs RB, Cory-Slechta DA, Neurotoxicology 2002 23 621 633 10.1016/S0161-813X(02) 00092-X 12428734 (Pubitemid 36527682)
34. Liposomal-glutathione provides maintenance of intracellular glutathione and neuroprotection in mesencephalic neuronal cells. Zeevalk GD, Bernard LP, Guilford FT, Neurochem Res 2010 35 1575 1587 10.1007/s11064-010-0217-0 20535554
35. Combined exposure to Maneb and Paraquat alters transcriptional regulation of neurogenesis-related genes in mice models of Parkinson's disease. Desplats P, Patel P, Kosberg K, Mante M, Patrick C, Rockenstein E, Fujita M, Hashimoto M, Masliah E, Mol Neurodegener 2012 7 49 10.1186/1750-1326-7-49 23017109
36. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Hoglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, Caille I, Hirsch EC, Nat Neurosci 2004 7 726 735 10.1038/nn1265 15195095 (Pubitemid 38859057)
37. Adult neurogenesis in Parkinson's disease. Marxreiter F, Regensburger M, Winkler J, Cellular and molecular life sciences: CMLS 2013 70 459 473 10.1007/s00018-012-1062-x 22766974
38. Parkin differently regulates presenilin-1 and presenilin-2 functions by direct control of their promoter transcription. Duplan E, Sevalle J, Viotti J, Goiran T, Bauer C, Renbaum P, Levy-Lahad E, Gautier CA, Corti O, Leroudier N, et al. Journal of molecular cell biology 2013 5 132 142 10.1093/jmcb/mjt003 23359614
39. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Zhang C, Lin M, Wu R, Wang X, Yang B, Levine AJ, Hu W, Feng Z, Proc Natl Acad Sci U S A 2011 108 16259 16264 10.1073/pnas.1113884108 21930938
40. Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity. Viotti J, Duplan E, Caillava C, Condat J, Goiran T, Giordano C, Marie Y, Idbaih A, Delattre JY, Honnorat J, et al. Oncogene 2013 10.1038/onc.2013.124
41. Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson's disease. Imam SZ, Zhou Q, Yamamoto A, Valente AJ, Ali SF, Bains M, Roberts JL, Kahle PJ, Clark RA, Li S, The Journal of neuroscience: the official journal of the Society for Neuroscience 2011 31 157 163 10.1523/JNEUROSCI.1833-10.2011
42. Nitric oxide and neurological disorders. Duncan AJ, Heales SJ, Mol Aspects Med 2005 26 67 96 10.1016/j.mam.2004.09.004 15722115 (Pubitemid 40250165)
43. Salidroside protects against MPP(+)-induced apoptosis in PC12 cells by inhibiting the NO pathway. Li X, Ye X, Li X, Sun X, Liang Q, Tao L, Kang X, Chen J, Brain Res 2011 1382 9 18 21241673
44. Apoptotic neuronal death in Parkinson's disease: involvement of nitric oxide. Singh S, Dikshit M, Brain Res Rev 2007 54 233 250 10.1016/j.brainresrev. 2007.02.001 17408564 (Pubitemid 46891075)
45. Role of nitric oxide in Parkinson's disease. Zhang L, Dawson VL, Dawson TM, Pharmacol Therapeut 2006 109 33 41 10.1016/j.pharmthera.2005.05.007 (Pubitemid 41740813)
46. Polymorphonuclear leukocyte nitrite content and antioxidant enzymes in Parkinson's disease patients. Barthwal MK, Srivastava N, Shukla R, Nag D, Seth PK, Srimal RC, Dikshit M, Acta neurologica Scandinavica 1999 100 300 304 10536916 (Pubitemid 29482553)
47. Overexpression of neutrophil neuronal nitric oxide synthase in Parkinson's disease. Gatto EM, Riobo NA, Carreras MC, Chernavsky A, Rubio A, Satz ML, Poderoso JJ, Nitric oxide: biology and chemistry / official journal of the Nitric Oxide Society 2000 4 534 539 10.1006/niox.2000.0288
48. Involvement of nitric oxide in neurodegeneration: a study on the experimental models of Parkinson's disease. Singh S, Das T, Ravindran A, Chaturvedi RK, Shukla Y, Agarwal AK, Dikshit M, Redox report: communications in free radical research 2005 10 103 109 10.1179/135100005X38842 15949131 (Pubitemid 44110218)
49. Understanding cell death in Parkinson's disease. Jenner P, Olanow CW, Ann Neurol 1998 44 72 84 9749577
50. Nitric oxide negatively regulates mammalian adult neurogenesis. Packer MA, Stasiv Y, Benraiss A, Chmielnicki E, Grinberg A, Westphal H, Goldman SA, Enikolopov G, Proc Natl Acad Sci U S A 2003 100 9566 9571 10.1073/pnas. 1633579100 12886012 (Pubitemid 37033968)
51. Neuronal nitric oxide synthase-derived nitric oxide inhibits neurogenesis in the adult dentate gyrus by down-regulating cyclic AMP response element binding protein phosphorylation. Zhu XJ, Hua Y, Jiang J, Zhou QG, Luo CX, Han X, Lu YM, Zhu DY, Neuroscience 2006 141 827 836 10.1016/j.neuroscience.2006.04.032 16735094 (Pubitemid 44102701)
52. Transcription factors p53 and HIF-1alpha as targets of nitric oxide. Brune B, von Knethen A, Sandau KB, Cell Signal 2001 13 525 533 10.1016/S0898-6568(01)00175-9 11483405 (Pubitemid 32722111)
53. Nitric oxide induces conformational and functional modifications of wild-type p53 tumor suppressor protein. Calmels S, Hainaut P, Ohshima H, Cancer research 1997 57 3365 3369 9269997 (Pubitemid 27355476)
54. Protein S-nitrosylation: purview and parameters. Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS, Nat Rev Mol Cell Bio 2005 6 150 166 10.1038/nrm1569 (Pubitemid 40215810)
55. Nitric oxide-mediated inhibition of Hdm2-p53 binding. Schonhoff CM, Daou MC, Jones SN, Schiffer CA, Ross AH, Biochemistry 2002 41 13570 13574 10.1021/bi026262q 12427017 (Pubitemid 35332692)
56. Protein nitration and nitrosylation by NO-donating aspirin in colon cancer cells: Relevance to its mechanism of action. Williams JL, Ji P, Ouyang N, Kopelovich L, Rigas B, Exp Cell Res 2011 317 1359 1367 10.1016/j.yexcr.2011.03. 001 21406194
57. p53 and Bax activation in 6-hydroxydopamine-induced apoptosis in PC12 cells. Blum D, Wu Y, Nissou MF, Arnaud S, Alim Louis B, Verna JM, Brain research 1997 751 139 142 10.1016/S0006-8993(96)01358-3 9098577 (Pubitemid 27122145)
58. A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism. Mandir AS, Simbulan-Rosenthal CM, Poitras MF, Lumpkin JR, Dawson VL, Smulson ME, Dawson TM, Journal of neurochemistry 2002 83 186 192 10.1046/j.1471-4159.2002.01144.x 12358742
59. Activation of p53 signaling initiates apoptotic death in a cellular model of Parkinson's disease. Nair VD, Apoptosis: an international journal on programmed cell death 2006 11 955 966 10.1007/s10495-006-6316-3 (Pubitemid 43876826)
60. The role of p53 in neuronal cell death. Morrison RS, Kinoshita Y, Cell death and differentiation 2000 7 868 879 10.1038/sj.cdd.4400741 11279532
61. p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Duan W, Zhu X, Ladenheim B, Yu QS, Guo Z, Oyler J, Cutler RG, Cadet JL, Greig NH, Mattson MP, Annals of neurology 2002 52 597 606 10.1002/ana.10350 12402257 (Pubitemid 35246863)
62. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L, Nature 1994 367 188 193 10.1038/367188a0 8114918 (Pubitemid 24031702)
63. Loss of p53 induces changes in the behavior of subventricular zone cells: implication for the genesis of glial tumors. Gil-Perotin S, Marin-Husstege M, Li J, Soriano-Navarro M, Zindy F, Roussel MF, Garcia-Verdugo JM, Casaccia-Bonnefil P, The Journal of neuroscience: the official journal of the Society for Neuroscience 2006 26 1107 1116 10.1523/JNEUROSCI.3970-05.2006 (Pubitemid 43237042)
64. P53- and CD95-associated apoptosis in neurodegenerative diseases. De la Monte SM, Sohn YK, Ganju N, Wands JR, Laboratory investigation; a journal of technical methods and pathology 1998 78 401 411 23991186 (Pubitemid 28207853)
65. p53 protein, interferon-gamma, and NF-kappaB levels are elevated in the parkinsonian brain. Mogi M, Kondo T, Mizuno Y, Nagatsu T, Neuroscience letters 2007 414 94 97 10.1016/j.neulet.2006.12.003 17196747 (Pubitemid 46241643)
66. Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Norris EH, Uryu K, Leight S, Giasson BI, Trojanowski JQ, Lee VM, The American journal of pathology 2007 170 658 666 10.2353/ajpath.2007. 060359 17255333 (Pubitemid 47339402)
67. Protection against HIV-1 gp120-induced brain damage by neuronal expression of human amyloid precursor protein. Mucke L, Abraham CR, Ruppe MD, Rockenstein EM, Toggas SM, Mallory M, Alford M, Masliah E, The Journal of experimental medicine 1995 181 1551 1556 10.1084/jem.181.4.1551 7699335
68. Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. Jaffrey SR, Erdjument-Bromage H, Ferris CD, Tempst P, Snyder SH, Nature cell biology 2001 3 193 197 10.1038/35055104 11175752 (Pubitemid 32118373)
69. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Uehara T, Nakamura T, Yao D, Shi ZQ, Gu Z, Ma Y, Masliah E, Nomura Y, Lipton SA, Nature 2006 441 513 517 10.1038/nature04782 16724068 (Pubitemid 44050153)
70. The fusion protein of respiratory syncytial virus triggers p53-dependent apoptosis. Eckardt-Michel J, Lorek M, Baxmann D, Grunwald T, Keil GM, Zimmer G, Journal of virology 2008 82 3236 3249 10.1128/JVI.01887-07 18216092 (Pubitemid 351429903)
71. TRPC1 regulates skeletal myoblast migration and differentiation. Louis M, Zanou N, Van Schoor M, Gailly P, Journal of cell science 2008 121 3951 3959 10.1242/jcs.037218 19001499